Early dexmedetomidine and postoperative RASS-defined examinability after microsurgical clipping for aneurysmal subarachnoid hemorrhage: a time-resolved 24-h landmark cohort study.
Ding G, Li X, et al. • Frontiers in neurology • 2026
Early postoperative dexmedetomidine after microsurgical clipping for aneurysmal subarachnoid hemorrhage was associated with greater post-landmark RASS-defined examinability (68% vs 55%, Hodges-Lehmann location shift 12 percentage points; 95% CI, 5-19), with bradycardia as the principal trade-off, though findings remain vulnerable to confounding by indication and do not establish a drug-specific causal effect or downstream clinical benefit.
Key Findings
Results
Early dexmedetomidine use was associated with greater time-weighted proportion of RASS-defined examinability during 24-72 hours after the landmark compared to non-use.
Examinable time during 24-72 hours was 68% in early dexmedetomidine users versus 55% in non-users.
The Hodges-Lehmann location shift was 12 percentage points (95% CI, 5-19).
The GEE-adjusted marginal difference was 11.8 points (95% CI, 4.1-19.5).
Among 120 patients alive and classifiable at 24 hours, 41 received early dexmedetomidine and 79 did not.
RASS-defined examinability was defined as RASS -2 to 0, without reference to the contemporaneous ordered target.
Results
Window-specific analysis showed a larger difference in examinability during 24-48 hours than during 48-72 hours, but the interaction was not formally confirmed.
Window-specific differences were 15.2 points (95% CI, 6.0-24.4) for the 24-48 hour window and 6.3 points (95% CI, -2.4 to 15.0) for the 48-72 hour window.
The exposure-by-window difference-in-differences was 8.9 points (95% CI, -3.6 to 21.4; p = 0.164), indicating the interaction was imprecise.
The descriptive concentration of effect during 24-48 hours was characterized as hypothesis-generating rather than confirmatory.
Hour-level states were modeled in consecutive 6-hour bins using generalized estimating equations (GEE).
Results
Early dexmedetomidine users had less post-landmark deep-sedation time, with directionally lower but imprecise differences in co-sedative exposure, dose, and duration.
Post-landmark deep-sedation time was lower in early dexmedetomidine users.
Post-landmark co-sedative exposure, dose, and duration differences were described as 'directionally lower but imprecise.'
The authors noted that post-landmark co-sedative measures were 'not independent validation' of the primary finding.
Ordered-target attainment as a key secondary endpoint was described as 'directionally concordant' with the primary result.
The primary association remained after adding ordered-target stratum and in the shared-target restriction analyses.
Results
Bradycardia was more frequent in early dexmedetomidine users compared to non-users and was identified as the principal safety trade-off.
Bradycardia occurred in 22.0% of early dexmedetomidine users versus 7.6% of non-users.
The risk difference for bradycardia was 14.4 percentage points (95% CI, 1.6-29.7).
Other safety estimates were described as 'imprecise.'
Bradycardia was explicitly characterized as 'the principal trade-off' of early dexmedetomidine use in this context.
Methods
The study identified important methodological limitations including retrospective design, single-center setting, no preregistration, and vulnerability to confounding by indication.
The study was retrospective, reviewing adults with aSAH treated with clipping at one center from October 2021 to October 2025.
The endpoint hierarchy was finalized after data analysis during peer review, and the study was not preregistered.
No multiplicity adjustment was applied, and all estimates are described as exploratory.
The authors stated findings 'remain vulnerable to confounding by indication and do not establish a drug-specific causal effect or downstream clinical benefit.'
123 patients were eligible, with 120 alive and classifiable at 24 hours included in the primary analysis.
Methods
The study defined early dexmedetomidine exposure as initiation within 24 hours after clipping with continuation for at least 2 hours, classified during the 0-24 hour window.
Early dexmedetomidine was defined as initiation within 24 hours after clipping and continuation for at least 2 hours.
Exposure was classified during the 0-24 hour period post-clipping.
The primary endpoint was the time-weighted proportion of observed 24-72 hour time in RASS-defined examinability (RASS -2 to 0).
The study context was microsurgical clipping for aneurysmal subarachnoid hemorrhage (aSAH), where sedation goals include preserving neurological examinability without compromising hemodynamics or nimodipine delivery.
What This Means
This research looked at whether giving a sedative medication called dexmedetomidine early after brain surgery (microsurgical clipping) for a type of bleeding stroke called aneurysmal subarachnoid hemorrhage (aSAH) helped keep patients in a state where doctors could still assess their neurological condition. After this type of surgery, doctors face a challenge: patients need sedation to be comfortable, but too much sedation makes it impossible to check whether the brain is recovering properly. The study compared 41 patients who received dexmedetomidine within the first 24 hours after surgery to 79 who did not, looking at how often patients were in a 'examinable' state of alertness during the 24-72 hours following surgery.
This research suggests that patients who received early dexmedetomidine spent more time in a state where neurological examination was possible — about 68% of the monitored time compared to 55% in those who did not receive it, a difference of about 12 percentage points. The difference appeared larger in the 24-48 hour window than the 48-72 hour window, though this pattern was not statistically confirmed and is considered preliminary. However, early dexmedetomidine users experienced bradycardia (a slowed heart rate) more often — about 22% versus 8% — which the authors identified as the main safety concern associated with its use.
This research is exploratory and has important limitations: it was a single-center retrospective study that was not preregistered, and the authors caution that the findings cannot prove dexmedetomidine directly caused the better outcomes, nor that better examinability leads to improved patient recovery. The study does not show whether this approach ultimately helps patients recover better from their stroke. The authors describe their findings as hypothesis-generating, meaning they support designing more rigorous future studies rather than changing current clinical practice on their own.
Ding G, Li X, Luo J, Tian L, Lan Q, Zhou W, et al.. (2026). Early dexmedetomidine and postoperative RASS-defined examinability after microsurgical clipping for aneurysmal subarachnoid hemorrhage: a time-resolved 24-h landmark cohort study.. Frontiers in neurology. https://doi.org/10.3389/fneur.2026.1908727